Fibromyalgia is a syndrome characterized by chronic widespread pain and associated with sleep disturbance, depression, fatigue, and cognitive dysfunction. Polypharmacy is commonly used, but supportive evidence is limited. Most fibromyalgia trials focus primarily on pain reduction with monotherapy. This trial compares a pregabalin-duloxetine combination to each monotherapy. Using a randomized, double-blind, 4-period crossover design, participants received maximally tolerated doses of placebo, pregabalin, duloxetine, and pregabalin-duloxetine combination-for 6 weeks. Primary outcome was daily pain (0-10); secondary outcomes included global pain relief, Fibromyalgia Impact Questionnaire, SF-36 survey, Medical Outcomes Study Sleep Scale, Beck Depression Inventory (BDI-II), adverse events, and other measures. Of 41 participants randomized, 39 completed $2 treatments. Daily pain during placebo, pregabalin, duloxetine, and combination was 5.1, 5.0, 4.1, and 3.7, respectively (P , 0.05 only for combination vs placebo, and pregabalin). Participants (%) reporting $moderate global pain relief were 18%, 39%, 42%, and 68%, respectively (P , 0.05 for combination vs placebo, pregabalin, and duloxetine). Fibromyalgia Impact Questionnaire scores were 42.9, 37.4, 36.0, and 29.8, respectively (P , 0.05 for combination vs placebo, pregabalin, and duloxetine). SF-36 scores were 50.2, 55.7, 56.0, and 61.2, respectively (P , 0.05 for combination vs placebo, pregabalin, and duloxetine). Medical Outcomes Study Sleep Scale scores were 48.9, 35.2, 46.1, and 32.1, respectively (P , 0.05 only for combination vs placebo, and duloxetine). BDI-II scores were 11.9, 9.9, 10.7, and 8.9, respectively (P , 0.05 only for combination vs placebo). Moderate-severe drowsiness was more frequent during combination vs placebo. Combining pregabalin and duloxetine for fibromyalgia improves multiple clinical outcomes vs monotherapy. Continued research should compare this and other combinations to monotherapy for fibromyalgia.
Introduction
Fibromyalgia is a clinical syndrome characterized by chronic widespread pain and frequently associated with sleep disturbance, depression, fatigue, and cognitive dysfunction. 9, 17, 24, 32 Fibromyalgia affects 2% to 8% of the population 9, 23, 33 and has been estimated to generate 3-fold to 5-fold greater health care costs vs matched controls. 6, 28 Varying levels of evidence support a diverse array of treatments for fibromyalgia including exercise, pharmacological, physical, psychological, and other therapies. 8, 9, 14, 17 In particular, the anticonvulsant, pregabalin, 18 and the antidepressant, duloxetine, 29 are 2 newer pharmacological therapies that are widely used and have received regulatory approval in several countries, for the treatment of fibromyalgia. Pregabalin and duloxetine are thought to reduce pain by different pharmacological actions thus providing a mechanistic rationale for combining the 2. Pooled evidence from multiple trials of these drugs, as monotherapies, suggests only partial benefit for most patients because of incomplete efficacy and/or intolerable side effects at higher drug doses. 8, 17 It is thus understandable that realworld prescribing studies indicate that a majority of patients concurrently receive multiple treatments for fibromyalgia to address the limitations of monotherapy. 5, 6, 27, 28 However, rigorous evidence for combining different treatments is limited, 25 and more high-quality studies are needed to identify specific treatment combinations that provide added benefit vs other combinations that are either harmful or cost-ineffective. 16 To address this knowledge gap and clinical need, this trial compares a pregabalin-duloxetine combination to each monotherapy for the management of fibromyalgia. fibromyalgia and aged 18 to 70 years were included. We used the 1990 American College of Rheumatology fibromyalgia diagnostic criteria 34 to be consistent with the vast majority of fibromyalgia trials of pregabalin and duloxetine that were published at the time of protocol development. It should also be noted that this trial was initiated before the publication of the 2010 ACR criteria for fibromyalgia. Eligible participants had sufficient cognitive function and language skills for the study, experienced daily pain ($4/10) for at least 3 months, with AST and ALT #20% and serum creatinine #50% greater than the upper normal limit. Exclusion criteria included the presence of a painful condition, including inflammatory rheumatic disease, as severe as (or worse than), but distinct from, their fibromyalgia. Other exclusion criteria were major organ system disease, hypersensitivity to any of the study medications, and a severe mood disorder as diagnosed by a psychiatrist and/or active suicidal ideation. Participants with a history of significant abuse of illicit drugs, prescription drugs, or alcohol and/or taking more than 200 mg oral morphine equivalents/day were excluded. Participants with uncontrolled hypertension, diabetes, HIV, narrow-angle glaucoma, or malignancies or participants enrolled in other investigational studies were excluded. Participants requiring continued treatment with medications that adversely interact with the study medications (eg, quinolone antibiotics, warfarin, agents inhibiting serotonin reuptake) or with hereditary problems of fructose intolerance, glucose galactose malabsorption, or sucrose isomaltase insufficiency were excluded. Pregnancy and lactation were exclusion criteria, and women of childbearing potential were required to receive a highly effective form of contraception.
Study design
This was a single-center, 4-period (6 weeks per period) crossover randomized double-blind trial of placebo (Pl), pregabalin (Pg), duloxetine (D), and the combination of pregabalin and duloxetine (C). Given ethical considerations of treating trial patients with placebo (and minimal pain treatment during dose taper/washout periods) and as per a pragmatic, add-on design, study medications were administered in addition to previously prescribed analgesics including acetaminophen, nonsteroidal anti-inflammatory drugs, and opioids (#200 mg oral morphine equivalents/day). As per a balanced Latin Square crossover, double-dummy design, participants were allocated, in a doubleblind randomized fashion, to 1 of 24 possible sequences. A trial pharmacist prepared a concealed allocation schedule by computer-randomizing these sequences, in blocks of 4, to a consecutive number series. Participants were assigned the next consecutive number and the corresponding sequence of study medications was dispensed. During each of the 4 treatment periods, 2 different sets of orally administered medication capsules were given (green capsules 5 pregabalin or a matching pregabalin placebo; blue capsules 5 duloxetine or a matching duloxetine placebo). For each set of capsules, active drug and placebo capsules were identical in appearance. During each treatment period, green capsules (ie, pregabalin or placebo) were administered twice daily (morning and evening) and blue capsules (ie, duloxetine or placebo) were administered once daily (evening). For each treatment, capsule contents were PLACEBO-green capsules 5 placebo; blue capsules 5 placebo; PREGABALIN ALONE-green capsules 5 pregabalin; blue capsules 5 placebo; DULOXETINE ALONE-green capsules 5 placebo; blue capsules 5 duloxetine; COMBINATIONgreen capsules 5 pregabalin; blue capsules 5 duloxetine. Capsule dosing schedules for each treatment period used a target daily dosage ceiling of 450 mg of pregabalin (ie, maximum 3 capsules twice daily) and 120 mg of duloxetine (ie, maximum 4 capsules daily in the evening).
Protocol
Participants completed a 7-day baseline pain diary after discontinuing gabapentin, pregabalin, duloxetine, and/or any other prohibited drugs. Participants were allowed to continue nonsteroidal anti-inflammatory agents, acetaminophen, and/or opioids (#200 mg oral morphine equivalents) at a steady dose. Any procedural therapies (eg, nerve blocks) were forbidden throughout the trial. The dose escalation schedule of each set of capsules was identical in each treatment period, although it could be possible to reach different maximal tolerated doses (MTD) during each treatment period. The first 24 days of each period involved escalation towards MTD or ceiling dose. Days 25 to 31 of each period involved stable dosing at MTD, or ceiling dose, for that treatment. Days 32 to 41 of each treatment period involved an 11-day dose taper and day 42 involved a 1-day complete washout. A research nurse telephoned participants twice weekly to evaluate adverse effects (AEs) and guide dose titration. With each dose increase, AEs (noted by open-ended questioning) were rated (mild, moderate, or severe), and if moderate or severe AEs were present, participants were asked if they could tolerate the current dose for another 2 to 3 days. If so, this dose was continued with the expectation that tolerance to AEs would develop. If AEs were intolerable, dose was decreased, but another increase was attempted again at a subsequent telephone call. If intolerable AEs were encountered again, study drugs were decreased back to the previous dose, which was defined as MTD. Participants choosing to withdraw from a study treatment period (eg, because of AEs) were offered the opportunity to pursue the next treatment in their sequence (as per the original randomized double-blind treatment sequence) after taper and washout of the current treatment.
Outcomes
The primary outcome was "average pain intensity over the past 24 hours" (0-10 numerical rating scale) rated each morning upon arising and averaged over 7 days at MTD. The rationale for using pain intensity as the primary outcome is that previous studies suggest that pain intensity is the outcome measure most sensitive to treatment with pregabalin and/or duloxetine. Secondary outcomes included worst pain intensity over the past 24 hours and average nocturnal pain intensity during sleeping hours both rated each morning upon arising and averaged over 7 days at MTD. Other secondary outcomes included global pain relief (pain worse, 21; no relief, 0; slight relief, 1; moderate relief, 2; a lot of relief, 3; or complete relief, 4), AEs/serious AEs, short-form McGill Pain Questionnaire, 26 Fibromyalgia Impact Questionnaire, 7 Brief Pain Inventory (BPI), 10 Beck Depression Inventory-II (BDI-II), 4 SF-36 Health Survey (SF-36), 31 Beck Anxiety Inventory, 3 Medical Outcomes Study Sleep Scale, 20 study drug MTDs, blinding questionnaires, number of tender points, body weight, and blood pressure.
Data analysis
The preplanned primary analysis was done to compare MTD average pain scores between combination and each monotherapy and placebo. Based on previous variance estimates and accounting for 6 pairwise comparisons, we calculated that approximately 49 trial completers would provide an 80% www.painjournalonline.com 1533 probability of detecting (2-sided alpha 5 0.05) a mean treatment difference of one-half of a clinically important 13 pain reduction. Participants completing at least 2 study treatment periods (providing at least 1 pairwise comparison) were included in the efficacy analysis. Participants receiving at least one dose of any study medication were included in AE analyses. Pain intensity was calculated as the average of diary scores during MTD if more than 50% of the scores were not missing. Otherwise, pain scores were treated as missing. A linear mixed model 22 with drug, sequence, period, and the first-order carryover term as the fixed effects and participant (nested in sequence) as the random effect were first fitted with the pain intensity data. If the carryover effect was not significant, then a reduced model excluding the carryover term was refitted. The least square mean and associated SDs estimated from the initial or reduced model were calculated for each treatment group. For the treatment effects, according to Fisher least significant difference method for multiple comparisons, 21 the global difference between all the treatment groups was first tested in the model. Only when this test was significant, all 6 pairwise comparisons were made using the estimated contrast from the initial or reduced model. As a secondary analysis for the primary outcome, "change in pain" during each period was calculated as the difference between "treatment period baseline" (mean of last 3 days of: pretrial baseline [for period A] or washouts [for periods B and C]) and average pain during MTD. The %change was calculated as "change in pain"/ "treatment period baseline" 3 100% and was analyzed as above using a linear mixed model. Secondary continuous outcomes were analyzed similarly. Proportions of participants with AEs were analyzed using Fisher exact method. 1 All reported P values are 2-sided. All analyses were conducted using SAS software.
Only 41 participants were recruited by the end of the trial funding period, in part, due to challenges for trial candidates to discontinue pretrial antidepressant treatments. Thus, an interim analysis, as defined here, was planned to assess the need to extend the trial period. This interim analysis was based on conditional power of the study (after adjustment of alpha for 2 comparisons), which is the chance of rejecting the null hypothesis at the end of the study (with 49 trial completers) calculated based on the trend of the difference observed from the 41 participants recruited. The interim analysis was performed (after 41 participants were recruited) by the statistician (D.T.) with rest of the members of the study team blinded to the 2 primary comparisons between combination and pregabalin or duloxetine. Only the conditional powers for the comparisons between combination and each of the monotherapies (blinded) were communicated to the study team. If both conditional powers were 50% or lower, trial accrual would be stopped. If one of the conditional powers was greater than 80%, the trial would also be stopped to declare superiority of the combination to one or both single agents and to conduct a complete analysis of the trial data set. Otherwise, the trial would remain open and the trial period would be extended so as to continue recruitment for all 49 participants. As discussed in the Results section, interim analysis results informed premature termination of the trial at 41 participants recruited.
Results

Subjects
Interim analysis, as described in the Methods, suggested only a 70% conditional power for the comparison between combination and duloxetine but a 100% conditional power for the comparison between combination and pregabalin. Therefore, after receiving these results from the trial statistician and, as per the above-defined interim analysis rules, the trial was prematurely terminated to declare superiority of the combination vs at least one of the monotherapies. Figure 1 describes participant flow through the trial. Forty-seven trial candidates were screened; 6 were excluded (1 declined to participate, 1 had medical exclusions, 2 had low pain intensity, 1 had second comorbid pain condition, 1 had inadequately treated depression) and 41 randomized; 1 patient was withdrawn after the first period washout (1 with pregabalin, related to AEs); 4 were withdrawn during/after the second period/washout (1 with placebo, 2 with duloxetine, 1 received combination, all related to AEs); 1 was withdrawn during/after the third period/washout (1 had duloxetine, related to AEs); and 3 were withdrawn during/after the fourth period/washout (3 received combination, 1 related to AEs, 1 for personal reasons, and 1 for a new-onset, self-limited flu-like illness). Two participants who were withdrawn during the second treatment period (1 duloxetine and 1 combination) accepted the offer to pursue the third treatment period. One participant who was withdrawn during the third treatment period (duloxetine) accepted the offer to pursue the fourth treatment period. One participant discontinued the entire trial at the end of period 1; 1 participant discontinued the trial during period 4, however, provided no data for any treatment period. Thirty-three participants completed all 4 periods. Thirty-nine participants completed at least 2 periods and were thus included in the efficacy analysis ( Figure 1) . Table 1 describes demographic and baseline characteristics of enrollees. Figure 2A outlines the trial design to facilitate understanding of trial results. Figure 2B illustrates average daily pain throughout Figure 1 . Flow of participants through the trial (see text for additional details). *Two participants who were withdrawn during the second treatment period (1 duloxetine and 1 combination) accepted the offer to pursue the third treatment period. †One participant who was withdrawn during the third treatment period (duloxetine) accepted the offer to pursue the fourth treatment period. §One participant discontinued the entire trial at the end of period 1; 1 participant discontinued the trial during period 4, however, provided no data for any treatment period.
Primary outcome
the trial for each treatment irrespective of treatment period order. Primary analysis revealed no significant effects of sequence (P 5 0.1) or carryover (P 5 0.87), but effects of period (P 5 0.0003, adjusted for in the primary analysis) and treatment (P , 0.001) were significant. Average pain (mean 6 SEM) at MTD was as follows: placebo 5 5.1 6 0.3; pregabalin 5 5.0 6 0.3; duloxetine 5 4.1 6 0.3; combination 5 3.7 6 0.3 (Fig. 2C) . Pain with combination was lower than placebo (P , 0.001) and pregabalin (P , 0.001). Pain with duloxetine was lower than placebo (P , 0.001) and pregabalin (P 5 0.003). Of note, the comparison of combination to duloxetine resulted in a P-value of 0.09. Secondary analyses of %change indicated greater reduction (%change 6 SEM) with combination (27.5% 6 6.0) vs pregabalin (1.4% 6 5.6, P 5 0.01) and placebo (27.1% 6 5.5, P 5 0.003).
Secondary outcomes
Proportions of participants reporting $moderate global pain relief at MTD were 18.4% on placebo, 38.5% on pregabalin, 41.7% on duloxetine, and 67.7% on combination. The P value for the comparisons were 0.03 between combination and duloxetine; 0.02 between combination and pregabalin; ,0.0001 between combination and placebo; 0.04 between duloxetine and placebo; 0.08 between pregabalin and placebo; and 0.82 between duloxetine and pregabalin. Worst pain at MTD with combination (4.5 6 0.3) was lower than placebo (6.0 6 0.3, P , 0.0001) and pregabalin (5.9 6 0.3, P , 0.0001); worst pain with duloxetine (4.8 6 0.3) was lower than placebo and pregabalin (P , 0.0001 and P 5 0.0002, respectively). Nocturnal pain at MTD with combination (3.2 6 0.4) was lower than placebo (4.4 6 0.3, P 5 0.0001) and pregabalin (4.2 6 0.4, P 5 0.0007) but failed to reach significance with duloxetine (3.8 6 0.3, P 5 0.052); nocturnal pain with duloxetine was lower than placebo (P 5 0.03). Short-form McGill Pain Questionnaire scores (Table 2) were 16.1, 13.5, 12.0, and 8.4, respectively, for placebo, pregabalin, duloxetine, and combination (P , 0.05 for the combination vs placebo, pregabalin, and duloxetine). Mean MTD dose of pregabalin in monotherapy (408.4 mg) was higher than that in combination (384.9 mg, P 5 0.02). Mean MTD dose of duloxetine in monotherapy (105.0 mg) was higher than that in combination (99.7 mg, P 5 0.04). Fibromyalgia Impact Questionnaire scores Table 2) were 11.9, 9.9, 10.7, and 8.9, respectively (P , 0.05 for the combination vs placebo). Beck Anxiety Inventory scores ( Table 2) were 10.0, 10.4, 9.5, and 8.3, respectively (no significant differences between treatments). BPI scores are shown in Table 2 . For "worst," "least," "average," and "right now" BPI pain scores, significant treatment differences were similar to those of the primary outcome measure (P , 0.05 for combination vs pregabalin and vs placebo; P , 0.05 for duloxetine vs pregabalin and vs placebo). For BPI interference scores ( Table 2) , pain interference with general activity, mood, walking, normal work, and social relations was significantly lower for combination and for duloxetine vs pregabalin and vs placebo (P , 0.05). Pain interference with sleep was significantly lower for combination and for pregabalin vs duloxetine and vs placebo (P , 0.05). Finally, pain interference with enjoyment of life was significantly lower for combination and for duloxetine vs placebo (P , 0.05). Table 3 shows self-reported AEs during dose titration, at MTD and during taper/washout. During titration, drowsiness was more frequent with combination (35.1%) vs placebo (7.5%, P 5 0.004); insomnia was less frequent with combination (18.9%) vs placebo (50%, P 5 0.008); insomnia was less frequent with pregabalin (20%) vs placebo (50%, P 5 0.009); and nausea was less frequent with pregabalin (5%) vs placebo (22.5%, P 5 0.05). At MTD, drowsiness was more frequent with combination (26.5%) vs duloxetine (5.3%, P 5 0.02) and also vs placebo (5.3%, P 5 0.02); insomnia was significantly more frequent with placebo (34.2%) vs combination (11.8%, P 5 0.03) and also vs pregabalin (7.9%, P 5 0.01). During study drug taper/washout, headache was more frequent with combination (29.4%) vs placebo (10%, P 5 0.04). Average numbers of tender points at MTD of each treatment were 14.7, 15.3, 14.7, and 15.2 for placebo, pregabalin, duloxetine, and combination, respectively, with no significant differences between treatments. Average body weight at MTD of each treatment was 79.5, 80.3, 78.9, and 79.7 for placebo, pregabalin, duloxetine, and combination, respectively. Body weight during duloxetine treatment was significantly lower than that for pregabalin (P 5 0.002). Average systolic blood pressure at MTD of each treatment was 123.1, 117.5, 122.0, and 116.0 for placebo, pregabalin, duloxetine, and combination, respectively. Systolic blood pressure was significantly lower during combination vs duloxetine (P 5 0.004) and vs placebo (P 5 0.0006); systolic blood pressure was significantly lower during pregabalin vs duloxetine (P 5 0.02) and vs placebo (P 5 0.004). Average diastolic blood pressure at MTD of each treatment was 77.5, 74.7, 78.0, and 74.3 for placebo, pregabalin, duloxetine, and combination, respectively. Diastolic blood pressure was significantly lower during combination vs duloxetine (P 5 0.005) and vs placebo (P 5 0.01); diastolic blood pressure was significantly lower during pregabalin vs duloxetine (P 5 0.009) and vs placebo (P 5 0.02). According to blinding questionnaire responses, correct guesses about treatment assignment among participants receiving placebo, pregabalin, duloxetine, and combination were made by 52%, 38%, 43%, and 31% of participants, respectively. Among participants receiving placebo, pregabalin, duloxetine, and combination, correct Table 1 Demographics and baseline characteristics of the patients. guesses made by the research nurse about treatment assignment were made for 45%, 29%, 43%, and 34%, respectively.
Discussion
This is the first randomized controlled trial, to our knowledge, comparing the combination of an antidepressant and an anticonvulsant to each monotherapy for the treatment of fibromyalgia. For the primary outcome of pain intensity, results of this trial demonstrate superiority of a pregabalin-duloxetine combination to pregabalin monotherapy; however, trends favouring combination over duloxetine monotherapy failed to reach significance. Because the interim analysis indicated a conditional probability of 70% for a significant difference between combination and duloxetine if the trial had continued to 49 trial completers, superiority of combination to duloxetine for this primary outcome cannot be ruled out. Although combination was not statistically superior to duloxetine for the primary outcome, this trial did demonstrate substantial and statistically significant superiority of combination to duloxetine monotherapy (as well as pregabalin) for global pain relief, functional improvement (Fibromyalgia Impact Questionnaire), and overall quality of life (SF-36 Health Survey) as well as for total scores of the ShortForm McGill Pain Questionnaire. Although drowsiness was significantly more frequent with combination (vs duloxetine alone), safety assessments conducted in this clinical trial cohort suggest that the pregabalin-duloxetine combination demonstrated a somewhat comparable tolerability profile vs either monotherapy. This is due, in part, to the method used of gradual dose titration to MTD during each treatment. In fact, the observation that significantly lower MTDs of pregabalin and duloxetine were reached during combination vs monotherapy suggests some overlap of side effect profiles of these 2 agents.
The pharmacological diversity of a pregabalin-duloxetine combination is a mechanistically appealing feature that increases the likelihood of additive analgesic actions, although there could similarly be some additive AEs with this combination. However, even at significantly lower doses during combination therapy, superior global pain relief during combination therapy would suggest a greater additive effect for pain reduction than for side effects. Because drowsiness with duloxetine and, even more so, pregabalin is not uncommon, one cannot rule out the possibility that physical activity was reduced with these treatments and that reduced physical activity could be one contributor to pain reduction. Thus, future analgesic trials that concurrently evaluate physical activity as well as pain may help clarify the complex interactions between analgesia, AEs, and physical function. The crossover design used for this trial allows for treatment comparison within each patient and thus maximizes the information gained from each individual. This strategy decreases sample size needed to achieve the same statistical power of a comparable parallel study. The validity of a crossover design requires that patients have stable endogenous pain levels in order for changes in pain during the trial to be attributed to the study treatments. Indeed, natural history and longer term follow-up studies suggest that pain in patients with fibromyalgia is quite stable over periods of 6 to 12 months, and crossover pain trials in fibromyalgia have shown that pain scores return towards baseline during treatment washout periods. Although the washout periods in this trial are relatively brief, the risk of "carryover" effects from one treatment period into the next is very low because each period is followed by an 11-day dose taper and a 1-day complete drug washout period and, more importantly, the final week at MTD for each period (from which the primary outcome is obtained) is separated from the next period's final week by 7 weeks (ie, at least 15 half-lives of the drugs studied). Indeed, the results of our trial analyses did not identify any carryover effect.
Although limitations of monotherapy for fibromyalgia are well recognized, the optimal management approach for participants enjoying only partial benefit with one agent remains unclear. Data showing that combination pharmacotherapy for fibromyalgia is common 5, 6, 27, 28 point to an important knowledge gap affecting clinical practice because the safety and efficacy of most drug combinations for fibromyalgia have not been rigorously evaluated. Previous consensus guidelines from the American Pain Society, European League Against Rheumatism, and the Association of the Scientific Medical Societies in Germany made no specific recommendations for, or against, combination pharmacotherapy for fibromyalgia. 19 More recently, however, joint guidelines from the Canadian Pain Society and Canadian Rheumatology Association 14 stated that "…An ideal pharmacological choice may address multiple symptoms simultaneously and may require a combination of medications, in which case attention must be paid to drug interactions (level 5, grade D)." The appearance of such a statement in widely disseminated treatment guidelines despite low-level evidence reflects both the perceived potential benefits of combination pharmacotherapy as well as the dire need for more high-quality supportive evidence to guide improved patient care. It should be noted that, because this trial population was limited to patients meeting the 1990 ACR criteria for fibromyalgia, it is possible that results from this trial could differ somewhat in a (likely broader) population of patients meeting the 2010 ACR criteria. Thus, it remains to be determined whether the results of this trial generalize to the broader population of patients meeting the 2010 ACR criteria and further replication is needed. Furthermore, this trial was developed before emerging evidence suggesting the possible overlap of, or interplay between, fibromyalgia and small fibre neuropathy, 30 and thus, we did not identify the presence or prevalence of small fibre neuropathy in our trial population. Because the results of this trial could potentially differ between fibromyalgia patients with or without small fibre neuropathy, future studies might benefit from pretrial evaluation for, and stratification according to presence of, small fibre neuropathy.
Incorporated into the design of this combination trial is a headto-head comparison between pregabalin monotherapy and duloxetine monotherapy. Thus, this is also the first trial we know of to directly compare an antidepressant with an anticonvulsant in fibromyalgia. As such, this trial suggests the superiority of duloxetine over pregabalin for the primary outcome of pain intensity as well as other subscales of the BPI. However, it should be noted that pregabalin was significantly superior to duloxetine for sleep improvement as per the Medical Outcomes Study Sleep scale measures.
In conclusion, the results of this trial suggest that combining pregabalin with duloxetine can safely improve outcomes in fibromyalgia, including pain relief, physical function, and overall quality of life. These benefits may come with a risk of increased drowsiness. Larger trials would be useful to replicate these results as well as other studies of different drug combinations that are currently used in practice with limited supportive evidence.
